ZIM Laboratories (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
ZIM Laboratories Limited |
|||
|
Price: ₹103.74 (-1.76%) | ||
| 52 Week Low: ₹89.50 52 Week High: ₹131.40 |
|||
| Market Capital: 525.5 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: ZIM Laboratories Share Price Target For 2025
- 1.1.1: ZIM Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: ZIM Laboratories Share Price Target For 2026
- 1.2.1: ZIM Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: ZIM Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: ZIM Laboratories Brief Company Overview
- 4: ZIM Laboratories Financial Performance
- 4.0.1: Is ZIM Laboratories A Good Buy For Long Term?
ZIM Laboratories, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 344.7% returns in 5-year showing 11.7% quarterly revenue growth with 4.6% profit margin, making it a potential Multibagger.
To predict the ZIM Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
ZIM Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of ZIM Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for ZIM Laboratories shares in 2025, see the table below.
ZIM Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 112.3 (+8.25%) | Price Action: 18 Sep 2024 Low |
| 2025 Target 2 | 111.15 (+7.14%) | Price Action: 22 Jan 2024 High |
| 2025 Target 1 | 110.04 (+6.07%) | Price Action: 24 Jul 2024 Low |
| Current Price | 103.74 | ZIM Laboratories's share price as of 21 Jan 2025 |
| Stop Loss 1 | 99.85 (-3.75%) | Price Action: 04 Apr 2024 High |
| Stop Loss 2 | 98.85 (-4.72%) | Price Action: 22 Mar 2024 Low |
| Stop Loss 3 | 97.85 (-5.68%) | Price Action: 04 Apr 2024 Low |
Short-Term Technical Outlook
Current Technical Position: ZIM Laboratories is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹106.69 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.78% | 6-month: -10.43% | 1-year: -3.45%
ZIM Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of ZIM Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for ZIM Laboratories shares in 2026, see the table below.
ZIM Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 163.32 (+57.43%) | Price Action: Chart |
| 2026 Target 2 | 160.27 (+54.49%) | Price Action: Chart |
| 2026 Target 1 | 158.68 (+52.95%) | Fibonacci Extension Level 64.90% |
| Current Price | 103.74 | ZIM Laboratories's share price as of 21 Jan 2025 |
| Stop Loss 1 | 90.0 (-13.25%) | Price Action: Oct 2022 High |
| Stop Loss 2 | 88.25 (-14.94%) | Price Action: Jul 2022 High |
| Stop Loss 3 | 86.66 (-16.47%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: ZIM Laboratories is currently trading at 34.0% of its 52-week range (₹89.5 - ₹131.4).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -3.45% | 3-year: +102.54% | 5-year: +344.66%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
ZIM Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹103.74 | ||
| 2025 | ₹155.03 | +49.44% | ₹157.36 |
| 2026 | ₹198.91 | +28.3% | ₹201.89 |
| 2027 | ₹272.69 | +37.09% | ₹276.78 |
| 2028 | ₹367.49 | +34.76% | ₹373.00 |
| 2029 | ₹425.16 | +15.69% | ₹431.54 |
| 2030 | ₹536.82 | +26.26% | ₹544.87 |
| 2031 | ₹609.53 | +13.54% | ₹618.67 |
| 2032 | ₹802.16 | +31.6% | ₹814.19 |
| 2033 | ₹911.04 | +13.57% | ₹924.71 |
| 2034 | ₹1,041.87 | +14.36% | ₹1,057.50 |
| 2035 | ₹1,216.54 | +16.76% | ₹1,234.79 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
ZIM Laboratories Brief Company Overview
ZIM Laboratories Limited: Enhancing Healthcare Worldwide Established in 1984 and headquartered in Nagpur, India, ZIM Laboratories Limited is a reputable manufacturer of generic pharmaceutical and nutraceutical products. The company's diverse product range...
encompasses pre-formulation intermediates and finished formulations in various oral solid dosage forms. ZIM's offerings extend across therapeutic areas such as urology, gastroenterology, CNS, antibiotics, anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM's commitment to innovation is evident in its modified release patterns, providing enhanced efficacy and patient convenience. With a strong presence in India and international markets, the company continues to contribute to global healthcare.ZIM Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 525.5 Crore | Market valuation of ZIM Laboratories's shares. |
| Revenue (TTM) | 372.6 Crore | Total revenue generated by ZIM Laboratories over the past twelve months. |
| Net Income (TTM) | +17.24 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +9.96% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +4.62% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+11.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+11.7% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
46.81 | Company's total debt divided by total shareholder equity. |
| Total Debt | 111.77 Crore | Sum of ZIM Laboratories's current & long-term financial obligations. |
| Total Cash | 10.46 Crore | Total amount of liquid funds available to ZIM Laboratories. |
Is ZIM Laboratories A Good Buy For Long Term?
ZIM Laboratories, a small-cap stock with a market cap of 525.5 Crore, has shown promising growth in the past three years (259.14%) and five years (122.05%). Despite a negative YTD return (-6.51%), its revenue and earnings have increased by 11.7% over the past quarter and year. While the company has a relatively high debt of 111.77 Crore, its net profit of 17.24 Crore over the last 12 months (TTM) indicates a profit margin of 4.62%. Given these factors, ZIM Laboratories appears to be an average buy for long-term investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
